Adrian W Quartel
CIK 1910132 · Chief Medical Officer · last filed 2026-07-29
Adrian W Quartel is a Chief Medical Officer who has filed 6 SEC Form 4 insider transactions across 3 companies since 2022. The most recent filing, for SPRB, was dated Jul 29, 2026. Across all open-market trades the lifetime net is −$40.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $88.7K across reported positions. 1 Form 144 notice of planned sales is also on file; the latest, for ZVRA on Jan 30, 2026, lists the filer as an officer.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZVRA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ONE GATEWAY CENTER, SUITE 351
NEWTON, MA 02458
Holdings By Company
10b5-1 Trading Plans
2 plans · 1 in force| Company | Adopted | Sales Can Start | Ends | Plan Allows | Sold So Far | Status | Link |
|---|---|---|---|---|---|---|---|
| ZVRA Chief Medical Officer |
Mar 16, 2026 | Jun 14, 2026 | Apr 30, 2027 | 225,000 shares | None filed | Active | 10-Q |
| ZVRA Chief Medical Officer |
Mar 26, 2025 | Jun 24, 2025 | Ended Mar 31, 2026 | 79,533 shares | 4,533 (6%) last filed Feb 2, 2026 |
Ended early | 10-Q |
Recent Filings
6 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-29 | SPRB | Grant (A) | — | $0 | EDGAR |
| 2026-02-02 | ZVRA | Mixed10b5-1 Plan adopted Mar 26, 2025 |
+6,800 | -$40.0K | EDGAR |
| 2026-01-30 | ZVRA | Notice (144) Officer · Planned Jan 30, 2026 · 10b5-1 plan Sold: Form 4 filed Feb 2, 2026 |
−4,533 | -$40.2K | EDGAR |
| 2025-03-27 | ZVRA | Grant (A) | — | $0 | EDGAR |
| 2023-03-16 | Acer Therapeutics Inc. (ACER) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-23 | Acer Therapeutics Inc. (ACER) Delisted | Grant (A) | — | $0 | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).